TY - JOUR T1 - Decreased antibody response among nursing home residents who received recalled influenza vaccine and results of revaccination, 1996-97. AU - Buxton Bridges,C, AU - Fukuda,K, AU - Holman,R C, AU - De Guzman,A M, AU - Hodder,R A, AU - Gomolin,I H, AU - Galligan,G K, AU - Leib,H B, AU - Gallo,R J, AU - Regnery,H L, AU - Arden,N H, AU - Cox,N J, PY - 1999/12/11/pubmed PY - 1999/12/11/medline PY - 1999/12/11/entrez SP - 1103 EP - 9 JF - Vaccine JO - Vaccine VL - 18 IS - 11-12 N2 - In November 1996, 11 lots of one U.S. manufacturer's 1996-97 trivalent influenza vaccine were voluntarily recalled because of decreasing potency of the A/Nanchang/933/95 (H3N2) component. Because the elderly are at high risk of developing influenza-related complications, we assessed the postvaccination antibody titers of nursing home residents who received recalled vaccine and assessed the antibody response to revaccination. Blood samples were collected 3 weeks after vaccination from 86 residents at three nursing homes who received recalled vaccine and 86 residents at three other nursing homes who received a different manufacturer's vaccine. Medical records were reviewed. Residents of one nursing home were later revaccinated. Blood samples were collected on the day of revaccination and again in 3 weeks. Serum was tested by hemagglutination inhibition for antibody to all three components of the 1996-97 influenza vaccine. The geometric mean antibody titer (GMT) (33 vs 55; p=0.01) and the percentage of residents with an antibody titer > or = 1:40 (52 vs 67%; p=0.04) to the A/Nanchang/933/95 component were lower among residents who received recalled vaccine compared to those who received non-recalled vaccine, but had similar GMTs against the other two vaccine components. After revaccination, the GMT to A/Nanchang/933/95 increased from 24 on the day of revaccination to 39 (p=0.01) in residents from one nursing home. Therefore, vaccination with the recalled vaccine was associated with lower postvaccination antibody titers to A/Nanchang/933/95, but not against the other two vaccine components. Revaccination was moderately effective in increasing antibody titers. With annual changes in influenza vaccine strains, routine post-release stability testing of influenza vaccine should continue. SN - 0264-410X UR - https://www.unboundmedicine.com/medline/citation/10590332/Decreased_antibody_response_among_nursing_home_residents_who_received_recalled_influenza_vaccine_and_results_of_revaccination_1996_97_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(99)00372-2 DB - PRIME DP - Unbound Medicine ER -